American Journal of Clinical Medicine Research
ISSN (Print): 2328-4005 ISSN (Online): 2328-403X Website: http://www.sciepub.com/journal/ajcmr Editor-in-chief: Dario Galante
Open Access
Journal Browser
Go
American Journal of Clinical Medicine Research. 2017, 5(3), 36-38
DOI: 10.12691/ajcmr-5-3-3
Open AccessArticle

Biodistribution of Gadolinium-DOTA-PAMAM Dendrimer Generation 3.0-Trastuzumab in Mice Organs

Deasy Biantong1 and Hari Soekersi1,

1Department of Radiology, Dr. Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia

Pub. Date: June 14, 2017

Cite this paper:
Deasy Biantong and Hari Soekersi. Biodistribution of Gadolinium-DOTA-PAMAM Dendrimer Generation 3.0-Trastuzumab in Mice Organs. American Journal of Clinical Medicine Research. 2017; 5(3):36-38. doi: 10.12691/ajcmr-5-3-3

Abstract

To know the biodistribution of compounds Gadolinium-DOTA-PAMAM dendrimer generation 3.0-Trastuzumab as a necessary ingredient MRI contrast agents in the organs of mice. Biodistribution test using the compound with radioactive marker 125I is injected intravenously into the blood vessel and distributed to the organs of mice were detected by gamma ray count tool. This research method is a descriptive study. Sampling applied with purposive random sampling technique. Research conducted in the laboratory animal center of Radioisotopes and Radiopharmaceuticals Technology National Nuclear Energy Agency (BATAN PTRR), Serpong, Indonesia. Analysis univariable illustrates the biodistribution of compounds Gadolinium-DOTA-PAMAM dendrimer G 3.0-trastuzumab in the organs of healthy mice regarding percentage per gram organ, bivariable analysis to assess differences in the biodistribution of Gadolinium-DOTA-PAMAM dendrimer G 3.0-Trastuzumab in the organs of mice. Biodistribution differences of Gadolinium-DOTA-PAMAM dendrimer G 3.0-trastuzumab injected intravenously in the organs of mice through percentage per gram organs. Percentage per gram organ compounds injected are highest in the blood, the peak accumulation is at 3 hours and declined in 72 hours, the smallest is in the brain. The liver is the largest organ of elimination for the compound (Gd-DOTA)n-PAMAM dendrimer G3.0-Trastuzumab-125I, peak accumulation is at 3 hours and decreased at 72 hours, then the kidney with the highest accumulated peak at 1 hour and declined to 72 hours.

Keywords:
biodistribution Gadolinium-DOTA-PAMAM dendrimer G 3.0-Trastuzumab Magnetic resonance imaging mice

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Zhou Z, Lu Z-R. Gadolinium-based contrast agents for magnetic resonance cancer imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013; 5(1): 1-18.
 
[2]  Rahmania H, Mutalib A, Ramli M, Levita J. Synthesis and stability test of radiogadolinium(III)-DOTA-PAMAM G3.0-trastuzumab as SPECT-MRI molecular imaging agent for diagnosis of HER-2 positive breast cancer. J Radiat Res Appl Sci. 2015; 8(1): 91-99.
 
[3]  Swanson SD, Kukowska-Latallo JF, Patri AK, Chen C, Ge S, Cao Z, et al. Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic renosance contrast enhancement. Int J Nanomedicine. 2008; 3(2): 201-210.
 
[4]  Gori S, Montemurro F, Spazzapan S, et al. Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Ann Oncol. 2012; 23(6):1436-1441.
 
[5]  Yavuz B, Pehlivan SB, Unlu N. Dendrimeric systems and their applications in ocular drug delivery. ScientificWorldJournal. 2013; 2013: 732340.
 
[6]  Opina AC, Wong KJ, Griffiths GL. Preparation and long-term biodistribution studies of a PAMAM dendrimer G5-Gd-BnDOTA conjugate for lymphatic imaging. Nanomedicine (Lond). 2015; 10(9): 1423-1437.
 
[7]  Vedha Hari BN, Kalaimagal K, Porkodi R, Gajula PK, Ajay JY. Dendrimer: Globular nanostructured materials for drug delivery. Int J Pharm Tech Res. 2012; 4(1): 432-451.
 
[8]  Gradishar WJ. Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. Ann Oncol. 2013; 24(10): 2492-2500.